THIS SITE IS INTENDED FOR UK AND IRELAND HEALTH PROFESSIONALS ONLY
CREATED BY LEO PHARMA

Home

Introducing Enstilar®

A once-daily 4 week topical combination plaque psoriasis treatment in a foam spray formulation1

Delivers highly effective results at week 4,*2,3 with visible signs of improvement as early as week 12,4

Is easy and convenient to apply once daily3

Is generally well tolerated1,5

*Study details

Study 1 (Leonardi C et al. 2015): A Phase III, multicentre (US), double-blind, vehicle-controlled, 4-week study. Treatment success was defined as clear or almost clear skin (for patients with ≥moderate disease at baseline) or clear skin (for patients with mild disease at baseline), according to PGA. 53.3% (n=172/323) of patients using Enstilar® achieved treatment success by week 4 vs. 4.8% (n=5/103) of patients using foam vehicle (OR, 30.3; 95% CI, 9.7 to 94.3; P<0.001).2

Study 2 (Koo J et al. 2016): A Phase II, multicentre, investigator-blinded study. Treatment success was defined as patients who achieved clear or almost clear skin with at least a two-step improvement according to the PGA scale. 54.6% (n=77/141) of patients using Enstilar® achieved treatment success by week 4 vs. 43.0% (n=58/135) of patients using calcipotriol/ betamethasone ointment (OR, 1.7; 95%CI, 1.1 to 2.8; P=0.025).3

CI, confidence interval; OR, odds ratio; PGA, physician’s global assessment.

References
  1. Enstilar® SPC. UK: www.medicines.org.uk / IE: www.medicines.ie. Last accessed: August 2018.
  2. Leonardi C et al. J Drugs Dermatol 2015; 14(12):1468–1477.
  3. Koo J et al. J Dermatolog Treat 2016; 27(2):120–127.
  4. Data on File: LEO90100 – 003 March 2016.
  5. Menter A et al. Poster presented at the 16th Annual Las Vegas Dermatology Seminar; Las Vegas, USA 5–7 November 2015.

UK/IE MAT-04321 V4
Date of preparation: September 2018